Drug Profile
Research programme: Bispecific T cell engager constructs - Amgen
Alternative Names: AMG CDH19XLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Amgen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
- Discontinued Solid tumours
Most Recent Events
- 28 Feb 2023 Discontinued - Preclinical for Solid tumours in USA (Intraperitoneal) (Amgen pipeline February 2023)
- 28 Feb 2023 Discontinued - Preclinical for Solid tumours in USA (IV) (Amgen pipeline February 2023)
- 28 Feb 2023 Early research in Cancer in USA (Parenteral) (Amgen pipeline February 2023)